文献速递胸部肿瘤

肺免疫预后指数对接受阿替利珠单抗治疗的NSCLC患者生存与缓解的预测价值评估:临床试验汇总分析

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
PubMed 文献 · J Thorac Oncol · 2019-04-15

该汇总分析纳入四项阿替利珠单抗治疗NSCLC临床试验的1489例患者个体数据,按治疗前衍生中性粒细胞与淋巴细胞比值大于3和乳酸脱氢酶大于正常上限分为良好、中等和不良LIPI三组。LIPI与总生存、无进展生存和缓解显著相关,良好、中等、不良组中位总生存分别为18.4、11.3和4.5个月;但多西他赛治疗患者中LIPI同样与生存和缓解相关,故LIPI并非ICI特异性预测标志物。

要点

  • 治疗前LIPI与阿替利珠单抗治疗NSCLC患者的总生存、无进展生存和缓解显著相关。
  • 良好、中等、不良LIPI组中位总生存分别为18.4、11.3和4.5个月。
  • 多西他赛治疗患者中LIPI同样与生存和缓解相关,LIPI并非ICI特异性预测标志物。

核心结论

  • 治疗前LIPI是一种便捷的预后标志物,能够识别阿替利珠单抗治疗患者中生存和缓解结局显著不同的组别。
  • LIPI也是化疗患者生存和缓解的预后标志物,因此并非ICI治疗的特异性预测标志物。

研究设计与样本

  • 对四项阿替利珠单抗治疗NSCLC临床试验的患者个体数据进行汇总分析。
  • 根据治疗前衍生中性粒细胞与淋巴细胞比值大于3和乳酸脱氢酶大于正常上限,将患者分为良好LIPI(0个危险因素)、中等LIPI(1个危险因素)和不良LIPI(2个危险因素)三组。
  • 主要结局为总生存。

主要发现

  • 汇总队列共1489例接受阿替利珠单抗治疗的患者,LIPI分组与总生存(p < 0.001)、无进展生存(p < 0.001)和缓解(p < 0.001)显著相关。
  • 良好LIPI组(n = 678)、中等LIPI组(n = 631)和不良LIPI组(n = 180)的中位总生存分别为18.4个月、11.3个月和4.5个月。
  • 在接受多西他赛治疗的患者(n = 687)中,LIPI同样与生存(p < 0.001)和缓解(p = 0.005)相关。

关键数值与推荐

  • 良好LIPI:0个危险因素;中等LIPI:1个危险因素;不良LIPI:2个危险因素(危险因素为治疗前衍生中性粒细胞与淋巴细胞比值大于3和乳酸脱氢酶大于正常上限)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is substantial variability in survival and response outcomes for patients using immune checkpoint inhibitors (ICIs), and predictive markers are required to guide treatment decisions. A lung immune prognostic index (LIPI) was recently developed to predict ICI treatment outcomes and we aim to evaluate whether LIPI is predictive of survival and response for patients treated with atezolizumab for advanced NSCLC. METHODS: Pooled analysis was performed of patient-level data of four clinical trials of atezolizumab for NSCLC. Based on pre-treatment derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal, patients were assigned to one of three groups: good LIPI, 0 risk factors; intermediate LIPI, 1 risk factor; or poor LIPI, 2 risk factors. The primary outcome was overall survival (OS). RESULTS: In a pooled cohort of 1,489 patients treated with atezolizumab, the LIPI group was significantly associated with OS (p < 0.001), progression-free survival (p < 0.001), and response (p < 0.001). Median OS for good (n = 678), intermediate (n = 631), and poor (n = 180) LIPI groups was 18.4 months, 11.3 months, and 4.5 months, respectively. Association between LIPI and OS was consistently identified across a range of atezolizumab-treated subgroups. For docetaxel-treated patients (n = 687), LIPI was similarly associated with survival (p < 0.001) and response (p = 0.005). CONCLUSIONS: Pre-treatment LIPI is a convenient prognostic marker able to identify atezolizumab-treated patient groups with significantly different survival and response outcomes. However, LIPI is also a prognostic marker of survival and response for patients treated with chemotherapy; thus, it is not specifically predictive for ICI treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Sorich MJ, Rowland A, Karapetis CS, et al. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. J Thorac Oncol. 2019. PMID: 30999110. doi:10.1016/j.jtho.2019.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。